GLP-1作動薬市場規模、シェア、動向、2033年までの世界予測

GLP-1作動薬市場 – 製品（オゼンピック、ウェゴビ、ムンジャロ）、分子（セマグルチド、チルゼパチド）、タイプ（特許取得済み、バイオシミラー）、製剤形態（単回投与、複数回投与、錠剤）、ROA（皮下注射、経口）、適応症（糖尿病、肥満） – 2033年までの世界予測

GLP-1作動薬市場は、予測期間中に13.0%のCAGRで成長し、2025年の644.2億米ドルから2033年には1,707.5億米ドルに達すると見込まれています。GLP-1作動薬市場は、いくつかの主要な推進要因により急速に拡大しています。1つの顕著な要因は、規制当局によるGLP-1薬の新規適応症承認数の増加です。これらの承認により、GLP-1作動薬の用途が当初の適応症を超えて拡大し、心血管疾患、アルツハイマー病、閉塞性睡眠時無呼吸、肥満などの新しい適応症を含む、より幅広い患者集団の治療が可能になります。これらの慢性疾患の世界的な有病率の上昇は、糖尿病や肥満に対する効果的な治療法を必要とする患者の増加に伴い、市場の堅調な成長をさらに後押ししています。同時に、GLP-1作動薬は、血糖コントロールの改善や大幅な体重減少など、臨床上の効果が実証されており、医療提供者による採用率が増加しています。

この調査レポートでは、GLP-1作動薬市場を、製品（オゼンピック、ウェゴヴィ、モウンジャロ、ゼップバウンド、リベルサス、トルリシティ、オルフォルグリプロン、カグリセマ、スルボデュチド、レタトルチド、セマグルチドバイオシミラー、その他のGLP-1バイオシミラー、その他の製品）、分子（セマグルチド、チルゼパチド、デュラグルチド、カグリリンチド・セマグルチド配合剤、オルフォルグリプロン、スルボデュチド、レタトルチド、その他の分子）、タイプ（特許取得済み、バイオシミラー）、形式（単回投与、複数回投与、錠剤）、適応症（糖尿病、肥満、その他の適応症）、投与経路（皮下、経口）、エンドユーザー（在宅ケア施設、フィットネス/体重管理施設、長期ケア施設、病院および専門クリニック）および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ）に分類しています。本レポートは、GLP-1作動薬市場の成長に影響を与える推進要因、制約要因、課題、機会など、主要な要因に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、各社の事業概要、提供製品、主要戦略、提携、パートナーシップ、契約に関する洞察が得られています。製品の発売・承認、事業拡大、買収、パートナーシップ、製品パイプライン、提携、契約は、GLP-1作動薬市場に関連する最近の動向です。

本レポートは、GLP-1作動薬市場全体とそのサブセグメントの収益数値に最も近い近似値を提供することで、市場リーダー企業や新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

本レポートでは、以下の点について洞察を提供しています。

• 市場の成長に影響を与える主要な推進要因（製造能力の拡大、GLP-1製剤の糖尿病専門分野からより幅広い治療選択肢への移行、肥満および2型糖尿病の罹患率の増加）、制約要因（厳格なコスト管理と保険者による規制）、機会（経口GLP-1製剤に関する研究の増加）、課題（偽造品および調合GLP-1製剤のグレーマーケット、安全性、忍容性、持続性の問題）の分析。
• 製品開発／イノベーション：GLP-1作動薬市場における新規承認および発売製品に関する詳細な洞察
• 市場開発：収益性の高い市場に関する包括的な情報 – 本レポートでは、様々な地域にわたる市場分析を提供しています。
• 市場多様化：GLP-1作動薬市場における新サービス、未開拓地域、最近の動向、投資に関する包括的な情報
• 競合評価：ノボノルディスク（デンマーク）、イーライリリー（米国）、サノフィ（フランス）をはじめとする主要企業の市場シェア、成長戦略、製品提供に関する詳細な評価。主要企業を詳細に分析し、主要戦略、製品の承認・発売、買収、提携、契約、協業、事業拡大、最近の動向、投資・資金調達活動、ブランド／製品比較分析、ベンダー評価、GLP-1作動薬市場における財務指標に関する洞察を提供しています。

The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. The GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the growing number of new indication approvals for GLP-1 drugs by regulatory agencies. These approvals extend the uses of GLP-1 agonists beyond initial indications, allowing for treatments in broader patient populations, including newer indications such as cardiovascular conditions, Alzheimer’s disease, obstructive sleep apnea, and obesity. The rising prevalence of these chronic conditions globally further supports strong market growth, as more patients require effective therapies for diabetes and obesity. In parallel, GLP-1 agonists offer proven clinical benefits such as improved glycemic control and significant weight reduction, increasing their adoption rates among healthcare providers.

The patented products segment accounted for the largest share of the GLP-1 agonists market by type in 2024.

Based on type, the GLP-1 agonists market is segmented into patented products and biosimilars. In 2024, the patented products accounted for the largest share of the market. As biosimilars are expected to gain adoption post-2026, patented products currently account for the complete market. However, with the semaglutide patent expiring in 2026 onwards, the market for biosimilars is expected to grow significantly thereafter. Patented GLP-1 agonists dominate prescribing patterns due to their robust clinical data, extensive safety profiles, and premium marketing investments. Additionally, the original GLP-1 makers have established broad insurance coverage, ensuring patient access despite high list prices. These factors are expected to support market growth.

By end user, the home-care settings and fitness/ weight management facilities accounted for the largest share in the GLP-1 agonists market in 2024.

Based on end user, the GLP-1 agonists market is segmented into home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals & specialty clinics. In 2024, the home-care settings and fitness/weight management facilities segment accounted for the largest share of the GLP-1 agonists market. The large share of this end-user segment can be attributed to the evolving patient needs and broader trends in obesity and diabetes management. Home care settings offer convenience and flexible dosing schedules for patients, especially as most GLP-1 therapies are available in easy-to-administer, subcutaneous or oral formats. This increases patient adherence, with many preferring to self-administer medications, particularly for long-term therapies targeting obesity and type 2 diabetes. The spike in obesity prevalence and the mainstreaming of preventive health have also made GLP-1 usage in home environments much more common, driving share growth in this segment.

The US dominated the GLP-1 agonists market in 2024.

In 2024, the US dominated the GLP-1 agonists market due to a convergence of demographic, healthcare, regulatory, and commercial factors. The US has one of the highest prevalence rates globally for both obesity and type 2 diabetes, which significantly expands the patient pool eligible for GLP-1 treatment. Advanced healthcare infrastructure and widespread physician awareness ensure swift adoption of new therapies, while robust insurance coverage and reimbursement help broad patient access.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply-side- 70% and Demand-side 30%
• By Designation: Managers – 45%, CXOs & Directors – 30%, and Executives – 25%
• By Region: North America – 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (US)
• Sanofi (France)
• Hansoh Pharmaceutical Group Co., Ltd. (China)
• Boehringer Ingelheim International GmbH (Germany)
• Innovent (China)
• Sun Pharmaceutical Industries Ltd. (India)
• Pegbio Co. Ltd (China)
• Structure Therapeutics (US)
• Viking Therapeutics (US)
• Amgen Inc. (Switzerland)
• Altimmune (US)
• Glenmark (India)
• Biocon (India)
• Teva Pharmaceuticals (Israel)
• Terns Pharmaceuticals, Inc. (US)
• VTV Therapeutics (US)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Hanmi Pharm Co., Ltd. (South Korea)
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
• Pfizer Inc. (US)
• MetaVia Inc (US)
• SCOHIA PHARMA, Inc. (Japan)
• Sciwind Biosciences Co., Ltd. (China)
• i2o Therapeutics, Inc. (US)
• Biomed Industries, Inc. (US)
• Neuraly Inc. (US)

Research Coverage

This research report categorizes the GLP-1 agonists market by product (ozempic, wegovy, mounjaro, zepbound, rybelsus, trulicity, orforglipron, cagrisema, survodutide, retatrutide, semaglutide biosimilars, other GLP-1 biosimilars, other products), molecule (Semaglutide, Tirzepatide, Dulaglutide, Cagrilintide semaglutide combination, Orforglipron, Survodutide, Retatrutide, Other molecules), type (patented, biosimilars), format (single-dose, multi-dose, tablets), indication (diabetes, obesity, other indications), route of administration (subcutaneous, oral), end user (home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals and specialty clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report’s scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the GLP-1 agonists market. A thorough analysis of the key industry players has provided insights into their business overview, products offered, key strategies, collaborations, partnerships, and agreements. Product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements are the recent developments associated with the GLP-1 agonists market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall GLP-1 agonists market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (expanding manufacturing capacity, shift of GLP-1 drugs from diabetes specialty to broader treatment option, growing prevalence of obesity and type 2 diabetes), restraints (stringent cost and payer controls), opportunities (increasing studies on oral GLP-1), and challenges (counterfeits and compounded GLP-1 gray market, safety, tolerability, persistence issues) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly approved and launched products of the GLP-1 agonists market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the GLP-1 agonists market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of key players, including Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players. A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product approvals and launches, acquisitions, partnerships, agreements, collaborations, expansions, recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 agonists market.

Table of Contents

1               INTRODUCTION              42

1.1           STUDY OBJECTIVES       42

1.2           MARKET DEFINITION   42

1.3           STUDY SCOPE   43

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 43

1.3.2        INCLUSIONS & EXCLUSIONS       44

1.3.3        YEARS CONSIDERED      45

1.3.4        CURRENCY CONSIDERED            46

1.4           STAKEHOLDERS               46

1.5           SUMMARY OF CHANGES               46

2               RESEARCH METHODOLOGY       48

2.1           RESEARCH DATA              48

2.1.1        SECONDARY DATA          48

2.1.1.1    Key objectives of secondary research                 49

2.1.2        PRIMARY DATA 49

2.1.2.1    Breakdown of primaries      50

2.1.2.2    Key objectives of primary research    50

2.2           MARKET SIZE ESTIMATION         51

2.2.1        REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)                 51

2.2.2        SECONDARY DATA & PRIMARY INTERVIEWS      52

2.2.3        SEGMENTAL MARKET SIZE ASSESSMENT              53

2.3           MARKET GROWTH FORECAST   54

2.4           DATA TRIANGULATION                55

2.5           STUDY ASSUMPTIONS  56

2.6           RISK ANALYSIS  57

3               EXECUTIVE SUMMARY  58

3.1           KEY INSIGHTS & MARKET HIGHLIGHTS 58

3.2           STRATEGIC IMPERATIVES FOR STAKEHOLDERS                 62

3.3           DISRUPTIVE TRENDS SHAPING GLP-1 AGONISTS MARKET               62

3.4           HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS                 63

4               PREMIUM INSIGHTS       64

4.1           GLOBAL GLP-1 AGONISTS MARKET SNAPSHOT 64

4.2           NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION AND COUNTRY, 2024           65

4.3           GLP-1 AGONISTS MARKET, BY FORMAT, 2024      65

4.4           GLP-1 AGONISTS MARKET, BY END USER, 2024   66

4.5           GLP-1 AGONISTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              66

4.6           UNMET NEEDS & WHITE SPACES              67

4.7           STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES                 67

4.7.1        STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES                 67

4.8           EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS                 68

4.9           INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES              68

4.10         GLP-1 AGONISTS PRODUCTION CAPACITY HIGHLIGHTS     69

4.11         KEY DRUG LAUNCHES EXPECTED, 2025–2033       69

4.12         SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES       70

5               MARKET OVERVIEW       71

5.1           INTRODUCTION              71

5.2           MARKET DYNAMICS       71

5.2.1        DRIVERS               72

5.2.1.1    Expanding manufacturing capacities of large pharmaceutical companies              72

5.2.1.2    Shift of GLP-1 drugs from diabetes specialty to broader treatment options 73

5.2.1.3    Rising prevalence of obesity and type-2 diabetes            74

5.2.2        RESTRAINTS      75

5.2.2.1    Stringent cost and payer controls      75

5.2.3        OPPORTUNITIES              76

5.2.3.1    Increasing studies on oral GLP-1      76

5.2.4        CHALLENGES    76

5.2.4.1    Counterfeits and compounded GLP-1 gray market        76

5.2.4.2    Safety, tolerability, and persistence issues        77

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       78

5.3.1        KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES          78

5.4           PRICING ANALYSIS          80

5.4.1        AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS,

BY KEY PLAYER, 2022–2024            80

5.4.2        AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS,

BY KEY PLAYER, 2022–2024            80

5.4.3        AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024           81

5.4.4        FACTORS IMPACTING GLP-1 AGONISTS PRICING                 83

5.5           INDUSTRY TRENDS         83

5.5.1        SHIFT OF WEEKLY INJECTABLES TOWARD ORALS AND MULTI-AGONISTS           83

5.5.2        VERTICAL INTEGRATION AND CAPACITY SCALE-UP TO MEET DEMAND                83

5.6           TECHNOLOGY ANALYSIS             84

5.6.1        KEY TECHNOLOGIES     84

5.6.1.1    Chemical synthesis               84

5.6.1.2    Recombinant DNA technology           85

5.6.2        COMPLEMENTARY TECHNOLOGIES       85

5.6.2.1    Peptelligence         85

5.6.2.2    PEGylation and polymer encapsulation            86

5.6.3        ADJACENT TECHNOLOGIES       86

5.6.3.1    Hydrogel depot technologies              86

5.6.3.2    Technologies for oral delivery of GLP-1 analogues        87

5.7           PIPELINE ANALYSIS        88

5.8           TECHNOLOGY/PRODUCT ROADMAP    92

5.9           VALUE CHAIN ANALYSIS               92

5.10         ECOSYSTEM ANALYSIS  93

5.10.1      ROLE IN ECOSYSTEM     94

5.11         PORTER’S FIVE FORCES ANALYSIS           95

5.11.1      THREAT OF NEW ENTRANTS      96

5.11.2      THREAT OF SUBSTITUTES          96

5.11.3      BARGAINING POWER OF SUPPLIERS       96

5.11.4      BARGAINING POWER OF BUYERS             96

5.11.5      INTENSITY OF COMPETITIVE RIVALRY 96

5.12         REGULATORY ANALYSIS               96

5.12.1      REGULATORY LANDSCAPE         96

5.12.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             97

5.13         KEY CONFERENCES & EVENTS, 2025–2026              100

5.14         CUSTOMER LANDSCAPE & BUYER BEHAVIOR    101

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           101

5.14.2      KEY BUYING CRITERIA  102

5.14.3      ADOPTION BARRIER & INTERNAL FRICTION      103

5.15         INVESTMENT/FUNDING SCENARIO        104

5.16         REIMBURSEMENT SCENARIO     105

5.17         IMPACT OF AI/GEN AI ON GLP-1 AGONISTS MARKET                 105

5.17.1      IMPACT AT DEVELOPMENT AND MANUFACTURING STAGES                 105

5.17.2      AI USE CASES     106

5.17.3      KEY COMPANIES IMPLEMENTING AI      106

5.17.4      FUTURE OF AI/GEN AI IN GLP-1 AGONIST DRUG DEVELOPMENT ECOSYSTEM     107

5.18         IMPACT OF 2025 TRUMP TARIFF ON GLP-1 AGONISTS MARKET               107

5.18.1      INTRODUCTION              107

5.18.2      KEY TARIFF RATES          108

5.18.3      PRICE IMPACT ANALYSIS             108

5.18.4      IMPACT ON REGION      108

5.18.4.1  North America      108

5.18.4.2  Europe   109

5.18.4.3  Asia Pacific            109

5.18.5      IMPACT ON END-USE INDUSTRIES          110

5.18.5.1  Hospitals & specialty centers              110

5.18.5.2  Long-term care facilities     110

6               GLP-1 AGONISTS MARKET, BY PRODUCT             111

6.1           INTRODUCTION              112

6.2           GLP-1 AGONISTS VOLUME MARKET ESTIMATION                 113

6.3           OZEMPIC             113

6.3.1        ANTICIPATED PATENT EXPIRY OF SEMAGLUTIDE STARTING IN 2026 AND EXPECTED NEW DRUG LAUNCHES TO NEGATIVELY IMPACT MARKET 113

6.4           TRULICITY          116

6.4.1        LOSS OF PATENT EXCLUSIVITY AND HIGH COMPETITIVE PRESSURE TO DISRUPT MARKET GROWTH                 116

6.5           MOUNJARO        119

6.5.1        DUAL MECHANISM AS BOTH GIP AND GLP-1 RECEPTOR AGONIST TO PROPEL ADOPTION            119

6.6           WEGOVY              122

6.6.1        INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT MARKET GROWTH     122

6.7           RYBELSUS           125

6.7.1        EASE OF ADMINISTRATION TO FUEL ADOPTION AMONG PATIENTS          125

6.8           ZEPBOUND        128

6.8.1        INCREASED FOCUS ON OBESITY MANAGEMENT TO INDICATE HUGE GROWTH POTENTIAL                 128

6.9           ORFORGLIPRON               131

6.9.1        ORFORGLIPRON TO GAIN HIGH POTENTIAL DUE TO DEVICE-FREE LOGISTICS AND NO FASTING WINDOW   131

6.10         CAGRISEMA        135

6.10.1      FOCUS ON CHRONIC WEIGHT MANAGEMENT AND TYPE 2 DIABETES TREATMENT TO SPUR MARKET GROWTH                 135

6.11         SURVODUTIDE 138

6.11.1      STRONG CLINICAL EFFICACY IN OBESITY AND METABOLIC DISEASE MANAGEMENT TO AID MARKET GROWTH             138

6.12         RETATRUTIDE  142

6.12.1      STRONG WEIGHT-LOSS SIGNALS IN PHASE-2 DIABETES AND GLOBAL PHASE-3 CLINICAL PIPELINE TO DRIVE MARKET                 142

6.13         SEMAGLUTIDE BIOSIMILARS     145

6.13.1      HIGH DEMAND FOR AFFORDABLE DIABETES AND OBESITY TREATMENTS TO AID GROWTH            145

6.14         OTHER GLP-1 BIOSIMILARS        149

6.15         OTHER PRODUCTS         152

7               GLP-1 AGONISTS MARKET, BY MOLECULE           155

7.1           INTRODUCTION              156

7.2           SEMAGLUTIDE 156

7.2.1        PROVEN EFFICACY IN SIGNIFICANT WEIGHT LOSS AND GLYCEMIC CONTROL TO SUPPORT GROWTH   156

7.3           TIRZEPATIDE    160

7.3.1        STRONG EFFECTIVENESS IN OBESITY TREATMENT TO ENHANCE PHYSICIAN CONFIDENCE AND PAYER INTEREST                 160

7.4           DULAGLUTIDE 163

7.4.1        USAGE IN PEDIATRIC TYPE 2 DIABETES FOR PATIENTS OVER 10 YEARS OLD TO ENHANCE USAGE IN SPECIALTY SETTINGS            163

7.5           CAGRILINTIDE SEMAGLUTIDE COMBINATION 166

7.5.1        SIGNIFICANT CLINICAL OUTCOMES IN WEIGHT MANAGEMENT TO DRIVE MARKET GROWTH     166

7.6           ORFORGLIPRON               170

7.6.1        NEEDLE-FREE ALTERNATIVE TO INCREASE CONVENIENCE AND SUPPORT ADOPTION AMONG PATIENTS                 170

7.7           SURVODUTIDE 173

7.7.1        DUAL GCG/GLP-1 RECEPTOR AGONISM AND FAVORABLE CLINICAL EVIDENCE TO AID GROWTH       173

7.8           RETATRUTIDE  177

7.8.1        TRIPLE-AGONIST APPROACH AND BEST-IN-CLASS WEIGHT MANAGEMENT FOR OBESITY TO SHOW HIGH GROWTH POTENTIAL   177

7.9           OTHER MOLECULES      180

8               GLP-1 AGONISTS MARKET, BY TYPE       184

8.1           INTRODUCTION              185

8.2           PATENTED PRODUCTS 185

8.2.1        PATENTED GLP-1 BRANDS TO SHIFT FROM WEIGHT LOSS DRUGS TO CARDIOMETABOLIC THERAPIES FOR BETTER ACCESS AND DURABILITY           185

8.3           BIOSIMILARS     189

8.3.1        SEMAGLUTIDE BIOSIMILARS     193

8.3.1.1    Upcoming patent expiry for major drugs in key markets to increase biosimilar adoption               193

8.3.2        OTHER BIOSIMILARS     197

9               GLP-1 AGONISTS MARKET, BY INDICATION        200

9.1           INTRODUCTIONS            201

9.2           DIABETES           201

9.2.1        HIGH DIABETES PREVALENCE TO FUEL MARKET ADOPTION         201

9.3           OBESITY              204

9.3.1        STRONG PIPELINE OF ANTI-OBESITY GLP-1 DRUGS TO DRIVE MARKET 204

9.4           OTHER INDICATIONS   207

10            GLP-1 AGONISTS MARKET, BY FORMAT                 211

10.1         INTRODUCTION              212

10.2         SINGLE-DOSE FORMATS               212

10.2.1      EASE OF ADMINISTRATION, DOSING AMOUNT PRECISION, AND LOW CONTAMINATION RISK TO SUPPORT MARKET GROWTH          212

10.3         MULTI-DOSE FORMATS                216

10.3.1      COST-EFFECTIVENESS AND LOW MEDICAL WASTE GENERATION TO AUGMENT ADOPTION IN HEALTHCARE SETTINGS            216

10.4         AUTOINJECTORS             219

10.4.1      SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION           219

11            GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION          223

11.1         INTRODUCTION              224

11.2         SUBCUTANEOUS ADMINISTRATION       224

11.2.1      PEN INJECTORS                228

11.2.1.1  Easy monitoring of volume and dosage strength to support adoption 228

11.2.2      AUTOINJECTORS             230

11.2.2.1  Simplified injection process with lower human errors to support adoption 230

11.3         ORAL ADMINISTRATION              233

11.3.1      ELIMINATION OF NEEDLEPHOBIA AND EASE OF USE TO DRIVE COMPLIANCE      233

12            GLP-1 AGONISTS MARKET, BY END USER              237

12.1         INTRODUCTION              238

12.2         HOME CARE SETTINGS AND FITNESS/ WEIGHT MANAGEMENT FACILITIES         238

12.2.1      RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH             238

12.3         LONG-TERM CARE FACILITIES  242

12.3.1      GROWING GERIATRIC POPULATION WITH CHRONIC DISEASES TO SUPPORT SEGMENT GROWTH       242

12.4         HOSPITALS & SPECIALTY CLINICS           245

12.4.1      ORGANIZED ENVIRONMENT, PROFESSIONAL OVERSIGHT, AND ABILITY TO HANDLE COMPLEX PATIENT NEEDS TO DRIVE MARKET          245

13            GLP-1 AGONISTS MARKET, BY REGION 249

13.1         INTRODUCTION              250

13.2         NORTH AMERICA             251

13.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 255

13.2.2      US           256

13.2.2.1  US to dominate North American GLP-1 agonists market during forecast period      256

13.2.3      CANADA               260

13.2.3.1  Favorable funding scenario and presence of strong research infrastructure to support market growth           260

13.3         EUROPE               264

13.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      268

13.3.2      GERMANY           269

13.3.2.1  Expertise in biotechnology and reputation as leading pharmaceutical manufacturing hub to expedite market growth    269

13.3.3      UK          273

13.3.3.1  Growing R&D initiatives for development of GLP-1 agonists drugs to support market growth         273

13.3.4      FRANCE                277

13.3.4.1  Favorable regulatory scenario and strong research infrastructure to propel market growth      277

13.3.5      ITALY    281

13.3.5.1  Presence of key pharmaceutical & biotechnology companies to boost market growth             281

13.3.6      SPAIN    285

13.3.6.1  High incidence of diabetes and obesity to augment market adoption of GLP-1 therapeutic drugs               285

13.3.7      NETHERLANDS 289

13.3.7.1  Strong focus on pharmaceutical R&D to support market growth                 289

13.3.8      REST OF EUROPE             293

13.4         ASIA PACIFIC     297

13.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 302

13.4.2      CHINA  303

13.4.2.1  Increasing endorsements of anti-obesity drugs by celebrities to drive market adoption          303

13.4.3      JAPAN   307

13.4.3.1  High diabetic population and favorable regulatory scenario to aid market growth       307

13.4.4      INDIA    311

13.4.4.1  Growing demand for cost-effective and accessible anti-obesity medications to aid market growth      311

13.4.5      AUSTRALIA         315

13.4.5.1  Significant government investment in obesity prevention to fuel market growth       315

13.4.6      SOUTH KOREA  319

13.4.6.1  Increasing strategic collaborations in obesity drugs to propel market growth       319

13.4.7      REST OF ASIA PACIFIC   323

13.5         LATIN AMERICA                327

13.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 331

13.5.2      BRAZIL 332

13.5.2.1  Increasing partnerships with global pharmaceutical companies and rising diabetes cases to drive Brazilian market         332

13.5.3      MEXICO                336

13.5.3.1  Growing diabetes and obesity prevalence to support market growth    336

13.5.4      REST OF LATIN AMERICA             340

13.6         MIDDLE EAST   344

13.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST                 348

13.6.2      GCC COUNTRIES              349

13.6.2.1  Kingdom of Saudi Arabia    353

13.6.2.1.1                Pricing oversight of Saudi Food and Drug Authority and strong sales from leading industry players to drive market            353

13.6.2.2  UAE        358

13.6.2.2.1                Growing regulatory approvals for GLP-1 drugs to spur market growth       358

13.6.2.3  Rest of GCC Countries        362

13.6.3      REST OF MIDDLE EAST 366

13.7         AFRICA 370

13.7.1      GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH 370

13.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        374

14            COMPETITIVE LANDSCAPE         375

14.1         INTRODUCTION              375

14.2         KEY STRATEGIES/RIGHT TO WIN             375

14.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET           375

14.3         REVENUE ANALYSIS, 2020–2024  377

14.4         MARKET SHARE ANALYSIS, 2024                 377

14.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 379

14.5.1      STARS   379

14.5.2      EMERGING LEADERS     379

14.5.3      PERVASIVE PLAYERS      379

14.5.4      PARTICIPANTS 380

14.6         COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024   381

14.6.1      STARS   381

14.6.2      EMERGING LEADERS     381

14.6.3      PERVASIVE PLAYERS      381

14.6.4      PARTICIPANTS 381

14.6.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         383

14.6.5.1  Company footprint               383

14.6.5.2  Region footprint   384

14.6.5.3  Format footprint   385

14.6.5.4  Route of administration footprint      385

14.6.5.5  Indication footprint              386

14.7         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        387

14.7.1      PROGRESSIVE COMPANIES         387

14.7.2      RESPONSIVE COMPANIES            387

14.7.3      DYNAMIC COMPANIES  387

14.7.4      STARTING BLOCKS         387

14.7.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 389

14.7.5.1  Competitive benchmarking of key startups/SMEs          390

14.8         COMPANY VALUATION & FINANCIAL METRICS 391

14.8.1      FINANCIAL METRICS      391

14.8.2      COMPANY VALUATION 391

14.9         BRAND/PRODUCT COMPARISON             392

14.10       COMPETITIVE SCENARIO             392

14.10.1   PRODUCT APPROVALS 392

14.10.2   DEALS  393

14.10.3   EXPANSIONS     394

14.10.4   OTHER DEVELOPMENTS              395

15            COMPANY PROFILES      396

15.1         INTRODUCTION              396

15.2         KEY PLAYERS     396

15.2.1      NOVO NORDISK A/S       396

15.2.1.1  Business overview 396

15.2.1.2  Products offered   397

15.2.1.3  Recent developments           398

15.2.1.3.1                Product approvals 398

15.2.1.3.2                Deals      399

15.2.1.3.3                Expansions             400

15.2.1.3.4                Other developments             400

15.2.1.4  MnM view              400

15.2.1.4.1                Right to win           400

15.2.1.4.2                Strategic choices   401

15.2.1.4.3                Weaknesses & competitive threats     401

15.2.2      ELI LILLY AND COMPANY            402

15.2.2.1  Business overview 402

15.2.2.2  Products offered   403

15.2.2.3  Recent developments           404

15.2.2.3.1                Product approvals 404

15.2.2.3.2                Deals      404

15.2.2.3.3                Expansions             405

15.2.2.4  MnM view              406

15.2.2.4.1                Right to win           406

15.2.2.4.2                Strategic choices   406

15.2.2.4.3                Weaknesses & competitive threats     406

15.2.3      SANOFI 407

15.2.3.1  Business overview 407

15.2.3.2  Products offered   408

15.2.3.3  MnM view              408

15.2.3.3.1                Key strengths        408

15.2.3.3.2                Strategic choices   408

15.2.3.3.3                Weaknesses & competitive threats     408

15.2.4      HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED              409

15.2.4.1  Business overview 409

15.2.4.2  Products offered   410

15.2.5      BOEHRINGER INGELHEIM INTERNATIONAL GMBH                 411

15.2.5.1  Business overview 411

15.2.5.2  Products offered (in pipeline)            412

15.2.5.3  Recent developments           413

15.2.5.3.1                Other developments             413

15.2.6      INNOVENT         414

15.2.6.1  Business overview 414

15.2.6.2  Products offered (in pipeline)            415

15.2.6.3  Recent developments           415

15.2.6.3.1                Product approvals 415

15.2.6.3.2                Other developments             416

15.2.7      PEGBIO CO., LTD.            417

15.2.7.1  Business overview 417

15.2.7.2  Products offered (in pipeline)            417

15.2.8      SCIWIND BIOSCIENCES CO., LTD.             418

15.2.8.1  Business overview 418

15.2.8.2  Products offered (in pipeline)            418

15.2.8.3  Recent developments           419

15.2.8.3.1                Deals      419

15.2.8.3.2                Other developments             419

15.2.9      ZEALAND PHARMA         420

15.2.9.1  Business overview 420

15.2.9.2  Products offered (in pipeline)            421

15.2.9.3  Recent developments           421

15.2.9.3.1                Deals      421

15.2.9.3.2                Other developments             421

15.2.10   STRUCTURE THERAPEUTICS, INC.           422

15.2.10.1                 Business overview 422

15.2.10.2                 Products offered (in pipeline)            422

15.2.10.3                 Recent developments           422

15.2.10.3.1             Other developments             422

15.2.11   VIKING THERAPEUTICS                423

15.2.11.1                 Business overview 423

15.2.11.2                 Products offered (in pipeline)            423

15.2.11.3                 Recent developments           424

15.2.11.3.1             Deals      424

15.2.12   SUN PHARMACEUTICAL INDUSTRIES LTD.          425

15.2.12.1                 Business overview 425

15.2.12.2                 Products offered (in pipeline)            426

15.2.13   VTV THERAPEUTICS      427

15.2.13.1                 Business overview 427

15.2.13.2                 Products offered (in pipeline)            427

15.2.14   ALTIMMUNE      428

15.2.14.1                 Business overview 428

15.2.14.2                 Products offered (in pipeline)            428

15.2.14.3                 Recent developments           429

15.2.14.3.1             Other developments             429

15.2.15   AMGEN INC.       430

15.2.15.1                 Business overview 430

15.2.15.2                 Products offered (in pipeline)            431

15.2.16   GLENMARK PHARMACEUTICALS LTD.   432

15.2.16.1                 Business overview 432

15.2.16.2                 Products offered (in pipeline)            433

15.2.16.3                 Recent developments           433

15.2.16.3.1             Product launches  433

15.2.17   BIOCON               434

15.2.17.1                 Business overview 434

15.2.17.2                 Products offered (in pipeline)            435

15.2.17.3                 Recent developments           436

15.2.17.3.1             Product launches and approvals         436

15.2.17.3.2             Deals      436

15.2.18   TEVA PHARMACEUTICAL INDUSTRIES LTD.       438

15.2.18.1                 Business overview 438

15.2.18.2                 Products offered (in pipeline)            439

15.2.18.3                 Recent developments           439

15.2.18.3.1             Product launches  439

15.2.19   F. HOFFMANN-LA ROCHE LTD. 440

15.2.19.1                 Business overview 440

15.2.19.2                 Products offered (in pipeline)            441

15.2.19.3                 Recent developments           442

15.2.19.3.1             Deals      442

15.3         OTHER PLAYERS              443

15.3.1      TERNS PHARMACEUTICALS, INC.             443

15.3.2      METAVIA             443

15.3.3      SCOHIA PHARMA, INC.  444

15.3.4      REGOR THERAPEUTICS GROUP                 444

15.3.5      NEURALY INC.   445

15.3.6      I2O THERAPEUTICS, INC.             445

15.3.7      PFIZER INC.        446

15.3.8      HANMI PHARM CO.,LTD.              446

15.3.9      JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.                 447

15.3.10   BIOMED INDUSTRIES, INC.          447

16            APPENDIX           448

16.1         DISCUSSION GUIDE        448

16.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                452

16.3         CUSTOMIZATION OPTIONS        454

16.4         RELATED REPORTS         454

16.5         AUTHOR DETAILS           455

LIST OF TABLES

TABLE 1                GLP-1 AGONISTS MARKET: INCLUSIONS & EXCLUSIONS      44

TABLE 2                GLP-1 AGONISTS MARKET: RISK ANALYSIS                 57

TABLE 3                GLP-1 AGONISTS MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES             67

TABLE 4                GLP-1 AGONISTS MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS           68

TABLE 5                EXPECTED KEY LAUNCHES IN GLP-1 AGONISTS MARKET, 2025–2033          69

TABLE 6                GLP-1 AGONISTS MARKET: IMPACT ANALYSIS                 72

TABLE 7                KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES          78

TABLE 8                AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)                 80

TABLE 9                AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024 (USD)         81

TABLE 10              GLP-1 AGONISTS IN CLINICAL PIPELINE (AS OF SEPTEMBER 2025)             88

TABLE 11              GLP-1 AGONISTS MARKET: ROLE IN ECOSYSTEM       94

TABLE 12              GLP-1 AGONISTS MARKET: PORTER’S FIVE FORCES                95

TABLE 13              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 97

TABLE 14              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           97

TABLE 15              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 98

TABLE 16              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 99

TABLE 17              LIST OF KEY CONFERENCES & EVENTS IN GLP-1 AGONISTS MARKET,

JANUARY 2025–DECEMBER 2026 100

TABLE 18              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE          101

TABLE 19              BUYING CRITERIA FOR GLP-1 AGONIST PRODUCTS, BY END USER            102

TABLE 20              GLP-1 AGONISTS: ADOPTION BARRIER & INTERNAL FRICTION     103

TABLE 21              KEY COMPANIES IMPLEMENTING AI IN GLP-1 AGONISTS MARKET        106

TABLE 22              GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)        112

TABLE 23              GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (MILLION UNITS)  113

TABLE 24              GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION)           113

TABLE 25              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY,

2024–2033 (USD BILLION)             114

TABLE 26              EUROPE: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY,

2024–2033 (USD BILLION)             114

TABLE 27              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY,

2024–2033 (USD BILLION)             115

TABLE 28              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY,

2024–2033 (USD BILLION)             115

TABLE 29              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION,

2024–2033 (USD BILLION)             115

TABLE 30              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY,

2024–2033 (USD BILLION)             116

TABLE 31              GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION)           116

TABLE 32              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY,

2024–2033 (USD BILLION)             117

TABLE 33              EUROPE: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY,

2024–2033 (USD BILLION)             117

TABLE 34              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY,

2024–2033 (USD BILLION)             118

TABLE 35              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY,

2024–2033 (USD BILLION)             118

TABLE 36              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION,

2024–2033 (USD BILLION)             118

TABLE 37              GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION,

2024–2033 (USD BILLION)             119

TABLE 38              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)                 120

TABLE 39              EUROPE: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY,

2024–2033 (USD BILLION)             120

TABLE 40              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY,

2024–2033 (USD BILLION)             121

TABLE 41              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY,

2024–2033 (USD BILLION)             121

TABLE 42              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION,

2024–2033 (USD BILLION)             121

TABLE 43              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY,

2024–2033 (USD BILLION)             122

TABLE 44              GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION)           122

TABLE 45              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY,

2024–2033 (USD BILLION)             123

TABLE 46              EUROPE: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY,

2024–2033 (USD BILLION)             123

TABLE 47              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY,

2024–2033 (USD BILLION)             124

TABLE 48              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY,

2024–2033 (USD BILLION)             124

TABLE 49              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION,

2024–2033 (USD BILLION)             124

TABLE 50              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY,

2024–2033 (USD BILLION)             125

TABLE 51              GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION)           125

TABLE 52              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY,

2024–2033 (USD BILLION)             126

TABLE 53              EUROPE: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY,

2024–2033 (USD BILLION)             126

TABLE 54              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY,

2024–2033 (USD BILLION)             127

TABLE 55              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY,

2024–2033 (USD BILLION)             127

TABLE 56              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION,

2024–2033 (USD BILLION)             127

TABLE 57              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY,

2024–2033 (USD BILLION)             128

TABLE 58              GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION,

2024–2033 (USD BILLION)           128

TABLE 59              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, S2024–2033 (USD BILLION)                 129

TABLE 60              EUROPE: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY,

2024–2033 (USD BILLION)             129

TABLE 61              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY,

2024–2033 (USD BILLION)             130

TABLE 62              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY,

2024–2033 (USD BILLION)             130

TABLE 63              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION,

2024–2033 (USD BILLION)             131

TABLE 64              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY,

2024–2033 (USD BILLION)             131

TABLE 65             GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION,

2024–2033 (USD BILLION)             132

TABLE 66              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 132

TABLE 67              EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY,

2024–2033 (USD BILLION)             133

TABLE 68              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 133

TABLE 69              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 134

TABLE 70              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION,

2024–2033 (USD BILLION)             134

TABLE 71              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 134

TABLE 72              GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION,

2024–2033 (USD BILLION)             135

TABLE 73              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)                 136

TABLE 74              EUROPE: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY,

2024–2033 (USD BILLION)             136

TABLE 75              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY,

2024–2033 (USD BILLION)             137

TABLE 76              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY,

2024–2033 (USD BILLION)             137

TABLE 77              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION,

2024–2033 (USD BILLION)             138

TABLE 78              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)                 138

TABLE 79              GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION,

2024–2033 (USD BILLION)             139

TABLE 80              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 139

TABLE 81              EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             140

TABLE 82              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             140

TABLE 83              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 141

TABLE 84              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION,

2024–2033 (USD BILLION)             141

TABLE 85              GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION,

2024–2033 (USD BILLION)             142

TABLE 86              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 143

TABLE 87              EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             143

TABLE 88              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             144

TABLE 89              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 144

TABLE 90              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION,

2024–2033 (USD BILLION)             145

TABLE 91              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 145

TABLE 92              GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION,

2024–2033 (USD BILLION)             146

TABLE 93              NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                146

TABLE 94              EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                147

TABLE 95              ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                147

TABLE 96              LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                148

TABLE 97              MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS,

BY REGION, 2024–2033 (USD BILLION)    148

TABLE 98              GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                148

TABLE 99              GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION,

2024–2033 (USD BILLION)             149

TABLE 100            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                149

TABLE 101            EUROPE: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)                 150

TABLE 102            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                150

TABLE 103            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                151

TABLE 104            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS,

BY REGION, 2024–2033 (USD BILLION)    151

TABLE 105            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS,

BY COUNTRY, 2024–2033 (USD BILLION)                151

TABLE 106            GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION,

2024–2033 (USD BILLION)             152

TABLE 107            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)             152

TABLE 108            EUROPE: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY,

2024–2033 (USD BILLION)             153

TABLE 109            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)                 153

TABLE 110            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)             154

TABLE 111            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION)                 154

TABLE 112            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)             154

TABLE 113            GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)             156

TABLE 114            GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION,

2024–2033 (USD BILLION)             157

TABLE 115            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 157

TABLE 116            EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             158

TABLE 117            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             158

TABLE 118            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 159

TABLE 119            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION,

2024–2033 (USD BILLION)             159

TABLE 120            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 159

TABLE 121            GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION,

2024–2033 (USD BILLION)             160

TABLE 122            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 161

TABLE 123            EUROPE: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY,

2024–2033 (USD BILLION)             161

TABLE 124            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY,

2024–2033 (USD BILLION)             162

TABLE 125            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 162

TABLE 126            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION,

2024–2033 (USD BILLION)             162

TABLE 127            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 163

TABLE 128            GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION,

2024–2033 (USD BILLION)             163

TABLE 129            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 164

TABLE 130            EUROPE: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             164

TABLE 131            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             165

TABLE 132            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 165

TABLE 133            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION,

2024–2033 (USD BILLION)             165

TABLE 134            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 166

TABLE 135            GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION,

BY REGION, 2024–2033 (USD BILLION)    167

TABLE 136            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)      167

TABLE 137            EUROPE: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)             168

TABLE 138            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)             168

TABLE 139            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)      169

TABLE 140            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION)             169

TABLE 141            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)      169

TABLE 142          GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION,

2024–2033 (USD BILLION)             170

TABLE 143            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 171

TABLE 144            EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY,

2024–2033 (USD BILLION)             171

TABLE 145            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 172

TABLE 146            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 172

TABLE 147            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION,

2024–2033 (USD BILLION)             172

TABLE 148            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)                 173

TABLE 149            GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION,

2024–2033 (USD BILLION)             174

TABLE 150            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 174

TABLE 151            EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             175

TABLE 152            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             175

TABLE 153            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 176

TABLE 154            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION,

2024–2033 (USD BILLION)             176

TABLE 155            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 176

TABLE 156            GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION,

2024–2033 (USD BILLION)             177

TABLE 157            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 178

TABLE 158            EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             178

TABLE 159            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY,

2024–2033 (USD BILLION)             179

TABLE 160            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 179

TABLE 161            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION,

2024–2033 (USD BILLION)             180

TABLE 162            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)                 180

TABLE 163            GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION,

2024–2033 (USD BILLION)             181

TABLE 164            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES,

BY COUNTRY, 2024–2033 (USD BILLION)                181

TABLE 165            EUROPE: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)   182

TABLE 166            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)                 182

TABLE 167            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)             183

TABLE 168            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION)                 183

TABLE 169            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES,

BY COUNTRY, 2024–2033 (USD BILLION)                183

TABLE 170            GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 185

TABLE 171            GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION,

2024–2033 (USD BILLION)             186

TABLE 172            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS,

BY COUNTRY, 2024–2033 (USD BILLION)                186

TABLE 173            EUROPE: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)                 187

TABLE 174            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)                 187

TABLE 175            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS,

BY COUNTRY, 2024–2033 (USD BILLION)                188

TABLE 176            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION)                 188

TABLE 177            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS,

BY COUNTRY, 2024–2033 (USD BILLION)                188

TABLE 178            GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION,

2024–2033 (USD BILLION)             189

TABLE 179            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)                 190

TABLE 180            EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY,

2024–2033 (USD BILLION)             190

TABLE 181            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY,

2024–2033 (USD BILLION)             191

TABLE 182            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)                 191

TABLE 183            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION,

2024–2033 (USD BILLION)             192

TABLE 184            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)                 192

TABLE 185            GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)          192

TABLE 186            SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)           194

TABLE 187            NORTH AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             194

TABLE 188            EUROPE: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             195

TABLE 189            ASIA PACIFIC: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             195

TABLE 190            LATIN AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             196

TABLE 191            MIDDLE EAST: SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION,

2024–2033 (USD BILLION)             196

TABLE 192            GCC COUNTRIES: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             196

TABLE 193            OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)             197

TABLE 194            NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             197

TABLE 195            EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      198

TABLE 196            ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             198

TABLE 197            LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             199

TABLE 198            MIDDLE EAST: OTHER BIOSIMILARS MARKET, BY REGION,

2024–2033 (USD BILLION)             199

TABLE 199            GCC COUNTRIES: OTHER BIOSIMILARS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             199

TABLE 200            GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)             201

TABLE 201            GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION)           202

TABLE 202            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY,

2024–2033 (USD BILLION)             202

TABLE 203            EUROPE: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY,

2024–2033 (USD BILLION)             202

TABLE 204            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY,

2024–2033 (USD BILLION)             203

TABLE 205            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY,

2024–2033 (USD BILLION)             203

TABLE 206            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION,

2024–2033 (USD BILLION)             203

TABLE 207            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY,

2024–2033 (USD BILLION)             204

TABLE 208            GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION)           205

TABLE 209            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY,

2024–2033 (USD BILLION)             205

TABLE 210            EUROPE: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY,

2024–2033 (USD BILLION)             205

TABLE 211            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY,

2024–2033 (USD BILLION)             206

TABLE 212            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY,

2024–2033 (USD BILLION)             206

TABLE 213            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION,

2024–2033 (USD BILLION)             206

TABLE 214            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY,

2024–2033 (USD BILLION)             207

TABLE 215            GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION,

2024–2033 (USD BILLION)             208

TABLE 216            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS,

BY COUNTRY, 2024–2033 (USD BILLION)                208

TABLE 217            EUROPE: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION) 209

TABLE 218            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)                 209

TABLE 219            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS,

BY COUNTRY, 2024–2033 (USD BILLION)                210

TABLE 220            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION)                 210

TABLE 221            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS,

BY COUNTRY, 2024–2033 (USD BILLION)                210

TABLE 222            GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)        212

TABLE 223            GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION,

2024–2033 (USD BILLION)             213

TABLE 224            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                213

TABLE 225            EUROPE: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)             214

TABLE 226            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                214

TABLE 227            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                215

TABLE 228            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS,

BY REGION, 2024–2033 (USD BILLION)    215

TABLE 229            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                215

TABLE 230            GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION,

2024–2033 (USD BILLION)             216

TABLE 231            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                217

TABLE 232            EUROPE: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)             217

TABLE 233            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)             218

TABLE 234            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                218

TABLE 235            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)                 218

TABLE 236            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS,

BY COUNTRY, 2024–2033 (USD BILLION)                219

TABLE 237            GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION)           220

TABLE 238            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY,

2024–2033 (USD BILLION)             220

TABLE 239            EUROPE: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY,

2024–2033 (USD BILLION)             220

TABLE 240            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY,

2024–2033 (USD BILLION)             221

TABLE 241            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY,

2024–2033 (USD BILLION)             221

TABLE 242            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION,

2024–2033 (USD BILLION)             221

TABLE 243            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY,

2024–2033 (USD BILLION)             222

TABLE 244            GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             224

TABLE 245            GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             225

TABLE 246            GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION) 225

TABLE 247            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)        225

TABLE 248            EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY COUNTRY, 2024–2033 (USD BILLION)                226

TABLE 249            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION) 226

TABLE 250            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)        227

TABLE 251            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION) 227

TABLE 252            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)        227

TABLE 253            PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION) 228

TABLE 254            NORTH AMERICA: PEN INJECTORS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             228

TABLE 255            EUROPE: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      229

TABLE 256            ASIA PACIFIC: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      229

TABLE 257            LATIN AMERICA: PEN INJECTORS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             229

TABLE 258            MIDDLE EAST: PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)           230

TABLE 259            GCC COUNTRIES: PEN INJECTORS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             230

TABLE 260            AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)        231

TABLE 261            NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             231

TABLE 262            EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      232

TABLE 263            ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      232

TABLE 264            LATIN AMERICA: AUTOINJECTORS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             232

TABLE 265            MIDDLE EAST: AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)           233

TABLE 266            GCC COUNTRIES: AUTOINJECTORS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             233

TABLE 267            GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION,

2024–2033 (USD BILLION)             234

TABLE 268            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION,

BY COUNTRY, 2024–2033 (USD BILLION)                234

TABLE 269            EUROPE: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)                 235

TABLE 270            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION,

BY COUNTRY, 2024–2033 (USD BILLION)                235

TABLE 271            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION,

BY COUNTRY, 2024–2033 (USD BILLION)                236

TABLE 272            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)                 236

TABLE 273            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION,

BY COUNTRY, 2024–2033 (USD BILLION)                236

TABLE 274            GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)        238

TABLE 275            GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024–2033 (USD BILLION)    239

TABLE 276            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY,

2024–2033 (USD BILLION)             239

TABLE 277            EUROPE: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY,

2024–2033 (USD BILLION)             240

TABLE 278            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY,

2024–2033 (USD BILLION)             240

TABLE 279            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY,

2024–2033 (USD BILLION)             241

TABLE 280            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION,

2024–2033 (USD BILLION)             241

TABLE 281            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY,

2024–2033 (USD BILLION)             241

TABLE 282            GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION,

2024–2033 (USD BILLION)             242

TABLE 283            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES,

BY COUNTRY, 2024–2033 (USD BILLION)                243

TABLE 284            EUROPE: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES,

BY COUNTRY, 2024–2033 (USD BILLION)                243

TABLE 285            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES,

BY COUNTRY, 2024–2033 (USD BILLION)                244

TABLE 286            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES,

BY COUNTRY, 2024–2033 (USD BILLION)                244

TABLE 287            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES,

BY REGION, 2024–2033 (USD BILLION)    244

TABLE 288            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES,

BY COUNTRY, 2024–2033 (USD BILLION)                245

TABLE 289            GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION)                 246

TABLE 290            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 246

TABLE 291            EUROPE: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS,

BY COUNTRY, 2024–2033 (USD BILLION)                247

TABLE 292            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS,

BY COUNTRY, 2024–2033 (USD BILLION)                247

TABLE 293            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 248

TABLE 294            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION)             248

TABLE 295            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION) 248

TABLE 296            GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION)        250

TABLE 297            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             252

TABLE 298            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             252

TABLE 299            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)          253

TABLE 300            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             253

TABLE 301            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             253

TABLE 302            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             254

TABLE 303            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 254

TABLE 304            NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 254

TABLE 305            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             255

TABLE 306            NORTH AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             255

TABLE 307            NORTH AMERICA: KEY MACROINDICATORS                 256

TABLE 308            US: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             257

TABLE 309            US: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)             258

TABLE 310            US: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)        258

TABLE 311            US: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             258

TABLE 312            US: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)             259

TABLE 313            US: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             259

TABLE 314            US: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             259

TABLE 315            US: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             260

TABLE 316            US: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             260

TABLE 317            CANADA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      261

TABLE 318            CANADA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   261

TABLE 319            CANADA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             262

TABLE 320            CANADA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             262

TABLE 321            CANADA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 262

TABLE 322            CANADA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         263

TABLE 323            CANADA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             263

TABLE 324            CANADA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          263

TABLE 325            CANADA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 264

TABLE 326            EUROPE: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      264

TABLE 327            EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      265

TABLE 328            EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   265

TABLE 329            EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             266

TABLE 330            EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             266

TABLE 331            EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 266

TABLE 332            EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         267

TABLE 333            EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             267

TABLE 334            EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          267

TABLE 335            EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 268

TABLE 336            EUROPE: KEY MACROINDICATORS          269

TABLE 337            GERMANY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      270

TABLE 338            GERMANY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   270

TABLE 339            GERMANY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             271

TABLE 340            GERMANY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             271

TABLE 341            GERMANY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 271

TABLE 342            GERMANY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         272

TABLE 343            GERMANY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             272

TABLE 344            GERMANY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          272

TABLE 345            GERMANY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 273

TABLE 346            UK: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             274

TABLE 347            UK: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)             274

TABLE 348            UK: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)        275

TABLE 349            UK: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             275

TABLE 350            UK: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)             275

TABLE 351            UK: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             276

TABLE 352            UK: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             276

TABLE 353            UK: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             276

TABLE 354            UK: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             277

TABLE 355            FRANCE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      278

TABLE 356            FRANCE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   278

TABLE 357            FRANCE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             279

TABLE 358            FRANCE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             279

TABLE 359            FRANCE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 279

TABLE 360            FRANCE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         280

TABLE 361            FRANCE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             280

TABLE 362            FRANCE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          280

TABLE 363            FRANCE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 281

TABLE 364          ITALY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             282

TABLE 365            ITALY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   282

TABLE 366            ITALY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             283

TABLE 367            ITALY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             283

TABLE 368            ITALY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 283

TABLE 369            ITALY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             284

TABLE 370            ITALY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             284

TABLE 371            ITALY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             284

TABLE 372            ITALY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             285

TABLE 373          SPAIN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             286

TABLE 374            SPAIN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   286

TABLE 375            SPAIN: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             287

TABLE 376            SPAIN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             287

TABLE 377            SPAIN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 287

TABLE 378            SPAIN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             288

TABLE 379            SPAIN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             288

TABLE 380            SPAIN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          288

TABLE 381            SPAIN: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             289

TABLE 382            NETHERLANDS: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             290

TABLE 383            NETHERLANDS: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             290

TABLE 384            NETHERLANDS: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 291

TABLE 385            NETHERLANDS: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             291

TABLE 386            NETHERLANDS: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             291

TABLE 387            NETHERLANDS: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             292

TABLE 388            NETHERLANDS: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 292

TABLE 389            NETHERLANDS: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             292

TABLE 390            NETHERLANDS: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             293

TABLE 391            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             294

TABLE 392            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             294

TABLE 393            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 295

TABLE 394            REST OF EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             295

TABLE 395            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             295

TABLE 396            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             296

TABLE 397            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 296

TABLE 398            REST OF EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 296

TABLE 399            REST OF EUROPE: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             297

TABLE 400            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)      298

TABLE 401            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      299

TABLE 402            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             299

TABLE 403            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 300

TABLE 404            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             300

TABLE 405            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             300

TABLE 406            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         301

TABLE 407            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             301

TABLE 408            ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             301

TABLE 409            ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             302

TABLE 410            ASIA PACIFIC: KEY MACROINDICATORS                 303

TABLE 411            CHINA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      304

TABLE 412            CHINA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   305

TABLE 413            CHINA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             305

TABLE 414            CHINA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             305

TABLE 415            CHINA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 306

TABLE 416            CHINA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             306

TABLE 417            CHINA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             306

TABLE 418            CHINA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          307

TABLE 419            CHINA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 307

TABLE 420          JAPAN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             308

TABLE 421            JAPAN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   308

TABLE 422            JAPAN: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             309

TABLE 423            JAPAN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             309

TABLE 424            JAPAN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 309

TABLE 425            JAPAN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             310

TABLE 426            JAPAN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             310

TABLE 427            JAPAN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          310

TABLE 428          JAPAN: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             311

TABLE 429          INDIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             312

TABLE 430            INDIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   312

TABLE 431            INDIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             313

TABLE 432            INDIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             313

TABLE 433            INDIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 313

TABLE 434            INDIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             314

TABLE 435            INDIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             314

TABLE 436            INDIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             314

TABLE 437            INDIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             315

TABLE 438            AUSTRALIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      316

TABLE 439            AUSTRALIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   316

TABLE 440            AUSTRALIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 317

TABLE 441            AUSTRALIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             317

TABLE 442            AUSTRALIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 317

TABLE 443            AUSTRALIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         318

TABLE 444            AUSTRALIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             318

TABLE 445            AUSTRALIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          318

TABLE 446            AUSTRALIA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 319

TABLE 447            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             320

TABLE 448            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             320

TABLE 449            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 321

TABLE 450            SOUTH KOREA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             321

TABLE 451            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             321

TABLE 452            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             322

TABLE 453            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             322

TABLE 454            SOUTH KOREA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             322

TABLE 455            SOUTH KOREA: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             323

TABLE 456            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             324

TABLE 457            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             324

TABLE 458            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE,

2024–2033 (USD BILLION)             325

TABLE 459            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)                 325

TABLE 460            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             325

TABLE 461            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             326

TABLE 462            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)             326

TABLE 463            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             326

TABLE 464            REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             327

TABLE 465            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             327

TABLE 466            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             328

TABLE 467            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 328

TABLE 468            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             329

TABLE 469            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             329

TABLE 470            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             329

TABLE 471            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 330

TABLE 472            LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 330

TABLE 473            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             330

TABLE 474            LATIN AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             331

TABLE 475            LATIN AMERICA: KEY MACROINDICATORS                 332

TABLE 476            BRAZIL: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      333

TABLE 477            BRAZIL: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   333

TABLE 478            BRAZIL: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             334

TABLE 479            BRAZIL: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             334

TABLE 480            BRAZIL: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 334

TABLE 481            BRAZIL: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             335

TABLE 482            BRAZIL: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             335

TABLE 483            BRAZIL: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          335

TABLE 484            BRAZIL: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 336

TABLE 485            MEXICO: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      337

TABLE 486            MEXICO: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   337

TABLE 487            MEXICO: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             338

TABLE 488            MEXICO: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             338

TABLE 489            MEXICO: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 338

TABLE 490            MEXICO: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         339

TABLE 491            MEXICO: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             339

TABLE 492            MEXICO: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          339

TABLE 493            MEXICO: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 340

TABLE 494            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             340

TABLE 495            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             341

TABLE 496            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE,

2024–2033 (USD BILLION)             341

TABLE 497            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)                 342

TABLE 498            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             342

TABLE 499            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             342

TABLE 500            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET,

BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 343

TABLE 501            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             343

TABLE 502            REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             343

TABLE 503            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             344

TABLE 504            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             345

TABLE 505            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 345

TABLE 506            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             346

TABLE 507            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             346

TABLE 508            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)         346

TABLE 509            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             347

TABLE 510            MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             347

TABLE 511            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             347

TABLE 512            MIDDLE EAST: GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION)           348

TABLE 513            MIDDLE EAST: KEY MACROINDICATORS                 349

TABLE 514            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             349

TABLE 515            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             350

TABLE 516            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION) 350

TABLE 517            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             351

TABLE 518            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             351

TABLE 519            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             351

TABLE 520            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 352

TABLE 521            GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION) 352

TABLE 522            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             352

TABLE 523            GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY COUNTRY,

2024–2033 (USD BILLION)             353

TABLE 524            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             354

TABLE 525            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             355

TABLE 526            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY TYPE,

2024–2033 (USD BILLION)             355

TABLE 527            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS,

BY TYPE, 2024–2033 (USD BILLION)          356

TABLE 528            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             356

TABLE 529            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             356

TABLE 530            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET,

BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 357

TABLE 531            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             357

TABLE 532            KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             357

TABLE 533            UAE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)             358

TABLE 534            UAE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)             359

TABLE 535            UAE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)        359

TABLE 536            UAE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             359

TABLE 537            UAE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 360

TABLE 538            UAE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             360

TABLE 539            UAE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             360

TABLE 540            UAE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             361

TABLE 541            UAE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)             361

TABLE 542            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             362

TABLE 543            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             363

TABLE 544            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE,

2024–2033 (USD BILLION)             363

TABLE 545            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)                 364

TABLE 546            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             364

TABLE 547            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             364

TABLE 548            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET,

BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 365

TABLE 549            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             365

TABLE 550            REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             365

TABLE 551            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT,

2024–2033 (USD BILLION)             366

TABLE 552            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE,

2024–2033 (USD BILLION)             367

TABLE 553            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE,

2024–2033 (USD BILLION)             367

TABLE 554            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)                 368

TABLE 555            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION,

2024–2033 (USD BILLION)             368

TABLE 556            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT,

2024–2033 (USD BILLION)             368

TABLE 557            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET,

BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)                 369

TABLE 558            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)             369

TABLE 559            REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER,

2024–2033 (USD BILLION)             369

TABLE 560            AFRICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)      370

TABLE 561            AFRICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)   371

TABLE 562            AFRICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)             371

TABLE 563            AFRICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)             372

TABLE 564            AFRICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION) 372

TABLE 565          AFRICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)             372

TABLE 566            AFRICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2024–2033 (USD BILLION)             373

TABLE 567            AFRICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,

BY TYPE, 2024–2033 (USD BILLION)          373

TABLE 568            AFRICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION) 373

TABLE 569            AFRICA: KEY MACROINDICATORS            374

TABLE 570            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN

GLP-1 AGONISTS MARKET           375

TABLE 571            GLP-1 AGONISTS MARKET: DEGREE OF COMPETITION 378

TABLE 572            GLP-1 AGONISTS MARKET: REGION FOOTPRINT (KEY PLAYERS)       384

TABLE 573            GLP-1 AGONISTS MARKET: REGION FOOTPRINT (PRODUCTS IN PIPELINE) 384

TABLE 574            GLP-1 AGONISTS MARKET: FORMAT FOOTPRINT       385

TABLE 575            GLP-1 AGONISTS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 385

TABLE 576            GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (KEY PLAYERS)       386

TABLE 577            GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (PRODUCTS IN PIPELINE) 386

TABLE 578            GLP-1 AGONISTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS    389

TABLE 579            GLP-1 AGONISTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY INDICATION AND REGION          390

TABLE 580            GLP-1 AGONISTS MARKET: PRODUCT APPROVALS,

JANUARY 2022–SEPTEMBER 2025                392

TABLE 581            GLP-1 AGONISTS MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025   393

TABLE 582            GLP-1 AGONISTS MARKET: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025                394

TABLE 583            GLP-1 AGONISTS MARKET: OTHER DEVELOPMENTS,

JANUARY 2022–SEPTEMBER 2025                395

TABLE 584            NOVO NORDISK A/S: COMPANY OVERVIEW                 396

TABLE 585            NOVO NORDISK A/S: PRODUCTS OFFERED                 397

TABLE 586            NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025                398

TABLE 587            NOVO NORDISK A/S: DEALS, JANUARY 2022–SEPTEMBER 2025              399

TABLE 588            NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025   400

TABLE 589            NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025                400

TABLE 590            ELI LILLY AND COMPANY: COMPANY OVERVIEW          402

TABLE 591            ELI LILLY AND COMPANY: PRODUCTS OFFERED                 403

TABLE 592            ELI LILLY AND COMPANY: PRODUCT APPROVALS,

JANUARY 2022–SEPTEMBER 2025                404

TABLE 593            ELI LILLY AND COMPANY: DEALS, JANUARY 2022–SEPTEMBER 2025   404

TABLE 594            ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025                405

TABLE 595            SANOFI: COMPANY OVERVIEW 407

TABLE 596            SANOFI: PRODUCTS OFFERED  408

TABLE 597            HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY OVERVIEW               409

TABLE 598            HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: PRODUCTS OFFERED                410

TABLE 599            BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW    411

TABLE 600            BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED

(IN PIPELINE)    412

TABLE 601            BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025        413

TABLE 602            INNOVENT: COMPANY OVERVIEW          414

TABLE 603            INNOVENT: PRODUCTS OFFERED (IN PIPELINE)                 415

TABLE 604            INNOVENT: PRODUCT APPROVALS, JANUARY 2022–SEPTEMBER 2025   415

TABLE 605            INNOVENT: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025   416

TABLE 606            PEGBIO CO., LTD.: COMPANY OVERVIEW                 417

TABLE 607            PEGBIO CO., LTD.: PRODUCTS OFFERED (IN PIPELINE)           417

TABLE 608            SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW          418

TABLE 609            SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS OFFERED (IN PIPELINE)                418

TABLE 610            SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025                419

TABLE 611            SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS,

JANUARY 2022–SEPTEMBER 2025                419

TABLE 612            ZEALAND PHARMA: COMPANY OVERVIEW                 420

TABLE 613            ZEALAND PHARMA: PRODUCTS OFFERED (IN PIPELINE)           421

TABLE 614            ZEALAND PHARMA: DEALS, JANUARY 2022–SEPTEMBER 2025              421

TABLE 615            ZEALAND PHARMA: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025                421

TABLE 616            STRUCTURE THERAPEUTICS, INC.: COMPANY OVERVIEW          422

TABLE 617            STRUCTURE THERAPEUTICS, INC.: PRODUCTS OFFERED (IN PIPELINE)                422

TABLE 618            STRUCTURE THERAPEUTICS, INC.: OTHER DEVELOPMENTS,

JANUARY 2022–SEPTEMBER 2025                422

TABLE 619            VIKING THERAPEUTICS: COMPANY OVERVIEW                 423

TABLE 620            VIKING THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE)    423

TABLE 621            VIKING THERAPEUTICS: DEALS, JANUARY 2022–SEPTEMBER 2025              424

TABLE 622            SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW   425

TABLE 623            SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED (IN PIPELINE)       426

TABLE 624            VTV THERAPEUTICS: COMPANY OVERVIEW                 427

TABLE 625            VTV THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE)           427

TABLE 626            ALTIMMUNE: COMPANY OVERVIEW       428

TABLE 627            ALTIMMUNE: PRODUCTS OFFERED (IN PIPELINE)           428

TABLE 628            ALTIMMUNE: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2025                429

TABLE 629            AMGEN INC.: COMPANY OVERVIEW        430

TABLE 630            AMGEN INC.: PRODUCTS OFFERED (IN PIPELINE)           431

TABLE 631            GLENMARK PHARMACEUTICALS LTD.: COMPANY OVERVIEW   432

TABLE 632            GLENMARK PHARMACEUTICALS LTD.: PRODUCTS OFFERED (IN PIPELINE)       433

TABLE 633            GLENMARK PHARMACEUTICALS LTD.: PRODUCT LAUNCHES,

JANUARY 2022–SEPTEMBER 2025                433

TABLE 634            BIOCON: COMPANY OVERVIEW                434

TABLE 635            BIOCON: PRODUCTS OFFERED (IN PIPELINE)                 435

TABLE 636            BIOCON: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–SEPTEMBER 2025                436

TABLE 637            BIOCON: DEALS, JANUARY 2022–SEPTEMBER 2025        436

TABLE 638            TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW   438

TABLE 639            TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED (IN PIPELINE)         439

TABLE 640            TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES,

JANUARY 2022–SEPTEMBER 2025                439

TABLE 641            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          440

TABLE 642            F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED (IN PIPELINE)                441

TABLE 643            F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–SEPTEMBER 2025                442

TABLE 644            TERNS PHARMACEUTICALS, INC.: COMPANY OVERVIEW          443

TABLE 645            METAVIA: COMPANY OVERVIEW              443

TABLE 646            SCOHIA PHARMA, INC.: COMPANY OVERVIEW                 444

TABLE 647            REGOR THERAPEUTICS GROUP: COMPANY OVERVIEW          444

TABLE 648            NEURALY INC.: COMPANY OVERVIEW   445

TABLE 649            I2O THERAPEUTICS, INC.: COMPANY OVERVIEW                 445

TABLE 650            PFIZER INC.: COMPANY OVERVIEW         446

TABLE 651            HANMI PHARM CO., LTD.: COMPANY OVERVIEW          446

TABLE 652            JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW       447

TABLE 653            BIOMED INDUSTRIES, INC.: COMPANY OVERVIEW          447

LIST OF FIGURES

FIGURE 1              GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE            43

FIGURE 2              GLP-1 AGONISTS MARKET: YEARS CONSIDERED                 45

FIGURE 3              GLP-1 AGONISTS MARKET: RESEARCH DESIGN                 48

FIGURE 4              BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS  50

FIGURE 5              GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024  51

FIGURE 6              GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024               51

FIGURE 7              MARKET VALIDATION FROM PRIMARY EXPERTS              52

FIGURE 8              GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH              53

FIGURE 9             CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 2025–2033              54

FIGURE 10            GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET               55

FIGURE 11            GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY         56

FIGURE 12            GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS. 2033 (USD BILLION) 58

FIGURE 13            GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION,

2025 VS. 2033 (USD BILLION)       59

FIGURE 14            GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS. 2030 (USD BILLION)       59

FIGURE 15            GLP-1 AGONISTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 60

FIGURE 16            REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET               61

FIGURE 17            INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY

TO PROPEL MARKET GROWTH 64

FIGURE 18            US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024        65

FIGURE 19            SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024                 65

FIGURE 20            HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 66

FIGURE 21            KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING

FORECAST PERIOD         66

FIGURE 22            GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES         71

FIGURE 23            US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS

(AS OF JANUARY 2024)   74

FIGURE 24            GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING

CUSTOMERS’ BUSINESSES           78

FIGURE 25            AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)                 80

FIGURE 26            GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS            92

FIGURE 27            GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS            94

FIGURE 28            GLP-1 AGONISTS MARKET: PORTER’S FIVE FORCES ANALYSIS           95

FIGURE 29            INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS,

BY TYPE               101

FIGURE 30            KEY BUYING CRITERIA FOR END USERS                 102

FIGURE 31            AI USE CASES IN GLP-1 AGONISTS MARKET                 106

FIGURE 32            NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT          251

FIGURE 33            ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT          298

FIGURE 34            REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET,

2020–2024 (USD BILLION)             377

FIGURE 35            MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024)              378

FIGURE 36            GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024         380

FIGURE 37            GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX

(PLAYERS WITH PRODUCTS IN PIPELINE), 2024 382

FIGURE 38            GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS)       383

FIGURE 39            GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE) 383

FIGURE 40            GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024                388

FIGURE 41            EV/EBITDA OF KEY VENDORS   391

FIGURE 42            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                391

FIGURE 43            GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS            392

FIGURE 44            NOVO NORDISK A/S: COMPANY SNAPSHOT                 397

FIGURE 45            ELI LILLY AND COMPANY: COMPANY SNAPSHOT          403

FIGURE 46            SANOFI: COMPANY SNAPSHOT 407

FIGURE 47            HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT               409

FIGURE 48            BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT   412

FIGURE 49            INNOVENT: COMPANY SNAPSHOT          414

FIGURE 50            ZEALAND PHARMA: COMPANY SNAPSHOT                 420

FIGURE 51            SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT   425

FIGURE 52            AMGEN INC.: COMPANY SNAPSHOT       431

FIGURE 53            GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT   432

FIGURE 54            BIOCON: COMPANY SNAPSHOT                435

FIGURE 55            TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT   438

FIGURE 56            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT          441

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧